|
Honoring Women GU Physician-Scientists Educating Through UroToday
As we celebrate Women's History Month, we recognize the many incredible women who have contributed to educating the global urology and oncology communities through UroToday-GU Oncology Today®. We deeply appreciate all the trailblazing women—both those pictured below and many others—whose knowledge and insights continue to advance the field. Thank you for your dedication to education and patient care.
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Gender Differences in Bladder Cancer Diagnosis, Treatment, and Patient Care |
Leslie Ballas, MD, and Elizabeth Guancial, MD
Leslie Ballas interviews Elizabeth Guancial about gender differences in bladder cancer presentation and treatment.
|
|
|
|
|
|
|
|
|
|
|
|
Treatment Options for Advanced Urothelial Cancer Post-EV-302
|
Shilpa Gupta, MD, and Karima Oualla, MD, MSc
Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta.
|
|
|
|
|
|
|
|
|
|
|
| Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians |
| Cora Sternberg, MD |
| Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. |
|
|
|
|
|
|
|
|
|
|
|
| Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation |
| Andrea Apolo, MD |
| Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer, focusing on the recent EV-302 and CheckMate-901 trials. |
|
|
|
|
|
|
|
|
|
|
|
|
BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer
|
|
Maha Hussain, MD, FACP, FASCO
|
| Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations.
|
|
|
|
|
|
|
|
|
|
|
|
|
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment
|
|
Louise Emmett, MD, MBChB, FRACP, FAANMS
|
| Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Enfortumab Vedotin and Pembrolizumab in Practice: A Case Study in Metastatic Urothelial Carcinoma |
| Brenda Martone, MSN, ANP-BC, AOCNP |
| Brenda Martone joins Alicia Morgans to discuss a case study of a 79-year-old patient treated with enfortumab vedotin and pembrolizumab following the EV-302 regimen for metastatic urothelial carcinoma. |
|
|
|
|
|
|
|
|
|
|
|
| CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC |
| Laurence Albiges, MD, PhD |
| Laurence Albiges joins Zachary Klaassen to discuss the CheckMate 67T trial results. |
|
|
|
|
|
|
|
|
|
|
|
| Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer |
| Sarah Psutka, MD, MS |
| Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer. |
|
|
|
|
|
|
|
|
|
|
|
|
Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France
|
| Srikala Sridhar, MD, MSc, FRCPC |
| Zachary Klaassen speaks with Srikala Sridhar about a publication comparing industry-sponsored trials (ISTs) and investigator-initiated trials (IITs) in advanced genitourinary cancers across the US, Canada, UK, and France. |
|
|
|
|
|
|
|
|
|
|
|
| IMPLEMENT Study Reveals Barriers to Treatment Intensification in Metastatic Prostate Cancer |
| Stacy Loeb, MD, MSc, PhD (Hon) |
| Neeraj Agarwal interviews Stacy Loeb about the IMPLEMENT study, which examines barriers to treatment intensification in metastatic hormone-sensitive prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| ARASTEP Trial Tests Darolutamide and ADT in High-Risk Biochemically Recurrent Prostate Cancer |
| Alicia Morgans, MD, MPH |
| Alicia Morgans discusses the ARASTEP trial, an ongoing registrational phase III trial which examines darolutamide plus ADT versus ADT and placebo in patients with high-risk biochemical recurrence identified by PSMA PET. |
|
|
|
|
|
|
|
|
|
|
|
| Adjuvant Systemic Therapies for Urothelial Carcinoma: Current Evidence and Future Directions |
| Jean Hoffman-Censits, MD |
| Jean Hoffman-Censits joins Sam Chang to discuss adjuvant systemic therapy approaches in urothelial carcinoma. |
|
|
|
|
|
|
|
|
|
|
|
|
The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist
|
|
Jean Hoffman-Censits, MD
|
| Cheryl Lee joins Zachary Klaassen to discuss the top 10 reasons why BCG as monotherapy for bladder cancer will likely cease to exist.
|
|
|
|
|
|
|
|
|
|
|
|
|
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial
|
|
Tian Zhang, MD, MHS
|
| Leslie Ballas and Tian Zhang discuss the STAR-EV trial, a new study combining enfortumab vedotin (EV) and radiation for muscle-invasive bladder cancer patients ineligible for cisplatin.
|
|
|
|
|
|
|
|
|
|
|
|
| First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer |
| Dana Rathkopf, MD |
| Oliver Sartor host Dana Rathkopf for a discussion on BMS-986365, a novel androgen receptor ligand-directed degrader for prostate cancer treatment. |
|
|
|
|
|
|
|
|
|
|
|
| Financial Distress for GU Cancer Patients: Insights from CDC Survey |
| Laura Bukavina, MD, MPH, MSc |
| Laura Bukavina and Steven Leonard discuss their study on financial distress for genitourinary cancer patients. |
|
|
|
|
|
|
|
|
|
|
|
|
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer
|
|
Amanda Nizam, MD
|
| Amanda Nizam presents findings from the UNITE study at GU ASCO 2024, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab
|
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials |
| Maria De Santis, MD, PhD |
| Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. |
|
|
|
|
|
|
|
|
|
